XML 52 R21.htm IDEA: XBRL DOCUMENT
v3.25.3

SHARE-BASED COMPENSATION | 12 Months Ended
--- | ---
Jul. 31, 2025
Share-Based Payment Arrangement [Abstract] |
SHARE-BASED COMPENSATION | NOTE 10: SHARE-BASED COMPENSATION On August 2, 2022, the Company approved an omnibus equity incentive plan (“Omnibus Plan”), which will permit the Company to grant incentive stock options, preferred share units, restricted share units (“RSU’s”), and deferred share units (collectively, the “Awards”) for the benefit of any employee, officer, director, or consultant of the Company or any subsidiary of the Company. The maximum number of shares available for issuance under the Omnibus Plan shall not exceed 15% of the issued and outstanding Shares, from time to time, less the number of Shares reserved for issuance under all other security-based compensation arrangements of the Company, including the existing Stock Option Plan. On February 9, 2023, the Omnibus Plan was approved by the shareholders. a. The following table summarizes the number of options granted under the Stock Option Plan for the year ended July 31, 2025 and related information: SUMMARY OF NUMBER OF OPTIONS GRANTED
|  | Number of options |  |  | Weighted average exercise price (*) |  |  | Weighted average remaining contractual term (in years) |  |  | Aggregate intrinsic value |
Balance as of July 31, 2023 and 2024 |  |  | 14,183 |  |  | $ | 923.53 |  |  |  | 2.52 |  |  | $ | - |
Granted (i) |  |  | 333 |  |  |  | 60.00 |  |  |  | 4.45 |  |  |  | - |
Forfeited |  |  | (1,265 | ) |  |  | 978.16 |  |  |  |  |  |  |  |  |
Balance as of July 31, 2025 |  |  | 13,251 |  |  |  | 896.61 |  |  |  | 1.62 |  |  |  | - |
Exercisable as of July 31, 2024 |  |  | 13,152 |  |  | $ | 924.60 |  |  |  | 2.41 |  |  | $ | - |
Exercisable as of July 31, 2025 |  |  | 13,251 |  |  | $ | 896.61 |  |  |  | 1.62 |  |  | $ | - |
| (i) | On January 16, 2025, the Company granted 333 stock options to a consultant at an exercise price of $60.00 per share. All options vested in full on April 16, 2025. The options expire on January 16, 2030. The grant-date fair value of the award was $16,242.
| (ii) | The weighted-average grant date per-share fair value of stock options granted during 2025 and 2024 was $48.77 and $ nil respectively. As of July 31, 2025, there are $nil of total unrecognized costs related to share-based compensation, as all costs have been fully recognized.
| (*) | certain options are exercisable in Canadian dollars and translated to US Dollars at year end.
BriaCell Therapeutics Corp Notes to the Consolidated Financial Statements For the Years Ended July 31, 2025 and 2024 (Expressed in US Dollars, except share and per share data and unless otherwise indicated) NOTE 10: SHARE-BASED COMPENSATION (Cont.) b. The following table lists the inputs to the Black-Scholes option-pricing model used for the fair value measurement of equity-settled share options for the above Options Plans granted for the years 2025 and 2024: SCHEDULE OF FAIR VALUE MEASUREMENT OF EQUITY - SETTLED SHARE OPTIONS
|  | Year ended July 31, |
|  | 2025 |  |  | 2024(*) |
Dividend yield |  |  | 0.00 | % |  |  | n/a |
Expected volatility of the share prices |  |  | 112 | % |  |  | n/a |
Risk-free interest rate |  |  | 4.45 | % |  |  | n/a |
Expected term (in years) |  |  | 5.0 |  |  |  | n/a |
(*) | There were no options grants during the year end July 31, 2024.
c. The following table summarizes information about the Company’s outstanding and exercisable options granted to employees as of July 31, 2025 SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS
Exercise price |  |  | Options outstanding as of July 31, 2025 |  |  | Weighted average remaining contractual term (years) |  |  | Options exercisable as of July 31, 2025 |  |  | Weighted average remaining contractual term (years) |  |  | Expiry Date
$ | 60.00 |  |  |  | 333 |  |  |  | 4.45 |  |  |  | 333 |  |  |  | 4.45 |  |  | January 16, 2030
$ | 904.50 |  |  |  | 2,663 |  |  |  | 2.89 |  |  |  | 2,663 |  |  |  | 2.89 |  |  | June 20, 2028
$ | 1,074.00 |  |  |  | 136 |  |  |  | 2.58 |  |  |  | 136 |  |  |  | 2.58 |  |  | February 27, 2028
$ | 907.97 |  |  |  | 1,195 |  |  |  | 2.01 |  |  |  | 1,195 |  |  |  | 2.01 |  |  | August 02, 2027
$ | 706.50 |  |  |  | 206 |  |  |  | 1.81 |  |  |  | 206 |  |  |  | 1.81 |  |  | May 20, 2027
$ | 1,126.50 |  |  |  | 1,000 |  |  |  | 1.54 |  |  |  | 1,000 |  |  |  | 1.54 |  |  | February 16, 2027
$ | 1,270.50 |  |  |  | 3,160 |  |  |  | 1.45 |  |  |  | 3,160 |  |  |  | 1.45 |  |  | January 13, 2027
$ | 1,074.83 |  |  |  | 81 |  |  |  | 1.25 |  |  |  | 81 |  |  |  | 1.25 |  |  | November 01, 2026
$ | 636.00 |  |  |  | 400 |  |  |  | 0.72 |  |  |  | 400 |  |  |  | 0.72 |  |  | April 19, 2026
$ | 636.00 |  |  |  | 4,077 |  |  |  | 0.66 |  |  |  | 4,077 |  |  |  | 0.66 |  |  | March 29, 2026
|  |  |  |  | 13,251 |  |  |  |  |  |  |  | 13,251 |  |  |  |  |  |  |
d. As result of the Arrangement, 2,131,400 BriaPro Options were issued and are outstanding as of July 31, 2025: SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS
Exercise Price |  |  | Options outstanding as of July 31, 2025 |  |  | Options exercisable as of July 31, 2025 |  |  | Expiry Date
$ | 0.0933 |  |  |  | 440,000 |  |  |  | 440,000 |  |  | June 20, 2028
$ | 0.1108 |  |  |  | 21,000 |  |  |  | 21,000 |  |  | February 27, 2028
$ | 0.0984 |  |  |  | 180,100 |  |  |  | 180,100 |  |  | August 02, 2027
$ | 0.0729 |  |  |  | 31,000 |  |  |  | 31,000 |  |  | May 20, 2027
$ | 0.1162 |  |  |  | 150,000 |  |  |  | 150,000 |  |  | February 16, 2027
$ | 0.1310 |  |  |  | 524,700 |  |  |  | 524,700 |  |  | January 13, 2027
$ | 0.1165 |  |  |  | 12,600 |  |  |  | 12,600 |  |  | November 01, 2026
$ | 0.0888 |  |  |  | 100,000 |  |  |  | 100,000 |  |  | September 01, 2026
$ | 0.0656 |  |  |  | 60,000 |  |  |  | 60,000 |  |  | April 19, 2026
$ | 0.0656 |  |  |  | 612,000 |  |  |  | 612,000 |  |  | March 29, 2026
|  |  |  |  | 2,131,400 |  |  |  | 2,131,400 |  |  |
BriaCell Therapeutics Corp Notes to the Consolidated Financial Statements For the Years Ended July 31, 2025 and 2024 (Expressed in US Dollars, except share and per share data and unless otherwise indicated) NOTE 10: SHARE-BASED COMPENSATION (Cont.) e. Restricted Share Units The following table summarizes the number of RSU’s granted to directors under the Omnibus Plan for year ended July 31, 2025: SCHEDULE OF RESTRICTED STOCK UNITS GRANTED
|  | Number of |  |  |  |
|  | RSU’s |  |  | Aggregate |
|  | outstanding |  |  | intrinsic value |
Balance, July 31, 2024 |  |  | 128 |  |  | $ | 14,400 |
Granted (i) |  |  | 6,166 |  |  |  | 370,000 |
Exercised(ii) |  |  | (6,294 | ) |  |  | (384,000 | )
Balance, July 31, 2025 |  |  | - |  |  | $ | - |
| (i) | On January 16, 2025, the Company granted 5,833 RSU’s to the Chief Executive Officer (“CEO”) as compensation for deferred salary, with immediate vesting. The fair value of these RSUs was $350,000, offsetting previously accrued compensation owed to the CEO. Additionally, on the same date, the Company granted 333 RSUs to a consultant, which fully vested on April 16, 2025. The fair value of these RSUs was $20,000.
| (ii) | All RSUs outstanding were exercised on July 13, 2025. As a result, no RSUs remained outstanding as of July 31, 2025.
f. The total share-based compensation expense related to all of the Company’s equity-based awards, recognized for the years ended July 31, 2025 and 2024 is comprised as follows: SCHEDULE OF SHARE-BASED COMPENSATION EXPENSES
|  | Year ended July 31, |
|  | 2025 |  |  | 2024 |
Research and development expenses |  | $ | 120,050 |  |  | $ | 734,986 |
General and administrative expenses |  |  | 656,829 |  |  |  | 1,069,092 |
Total share-based compensation |  | $ | 776,879 |  |  | $ | 1,804,078 |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration